<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879241</url>
  </required_header>
  <id_info>
    <org_study_id>RAS-ALS</org_study_id>
    <secondary_id>2011-004482-32</secondary_id>
    <nct_id>NCT01879241</nct_id>
  </id_info>
  <brief_title>Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to investigate the survival time (the time from&#xD;
      randomization until death or end of the trial) compared between control group and&#xD;
      experimental group.&#xD;
&#xD;
      This is a prospective, multicenter, randomized, stratified, parallel-group, double-blind&#xD;
      trial comparing placebo with 1 mg/d rasagiline as add-on therapy to 100 mg riluzole in&#xD;
      amyotrophic lateral sclerosis (ALS) in 250 enrolled patients. For entry, the El Escorial&#xD;
      Criteria for the diagnosis of ALS will be used. The patients have to be stable on riluzole at&#xD;
      least 4 weeks prior to randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in ALS-Patients with Rasagiline compared to placebo</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of slow vital capacity</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rasagiline&#xD;
1 mg/day; 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily, 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <arm_group_label>Rasagiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a sugar pill manufactured to mimic Rasagiline 1 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Possible, probable (clinically or laboratory) or definite ALS according to the revised&#xD;
             version of the El Escorial World Federation of Neurology criteria&#xD;
&#xD;
          -  Disease duration more than 6 months and less than 3 years (inclusive). Disease onset&#xD;
             defined as date of first muscle weakness, excluding fasciculations and cramps&#xD;
&#xD;
          -  Vital capacity more than 50% of normal (slow vital capacity; best of three&#xD;
             measurements)&#xD;
&#xD;
          -  Age: ≥ 18 years&#xD;
&#xD;
          -  Continuously treated with 100 mg riluzole for at least four weeks&#xD;
&#xD;
          -  Capable of thoroughly understanding all information given and giving full informed&#xD;
             consent according to GCP&#xD;
&#xD;
          -  Women of childbearing age must be non-lactating and surgically sterile or using a&#xD;
             highly effective method of birth control and have a negative pregnancy test.&#xD;
             Acceptable methods of birth control with a low failure rate i.e. less than 1% per&#xD;
             year) when used consistently and correct are such as implants, injectables, combined&#xD;
             oral contraceptives, hormonal intrauterine devices (IUDs), or double-barrier methods&#xD;
             (condom or diaphragm with spermicidal agent or IUD), sexual abstinence or vasectomized&#xD;
             partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in another clinical study within the preceding 12 weeks&#xD;
&#xD;
          -  Tracheostomy or assisted ventilation of any type during the preceding three months&#xD;
&#xD;
          -  Gastrostomy&#xD;
&#xD;
          -  Any medical condition known to have an association with motor neuron dysfunction which&#xD;
             might confound or obscure the diagnosis of ALS&#xD;
&#xD;
          -  Presence of any concomitant life-threatening disease or impairment likely to interfere&#xD;
             with functional assessment&#xD;
&#xD;
          -  Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine,&#xD;
             phenylpropanolamine, and ephedrine.&#xD;
&#xD;
          -  Patients on analgesics with serotoninergic properties such as meperidine, tramadol,&#xD;
             methadone and propoxyphene.&#xD;
&#xD;
          -  Patients on serotonin reuptake inhibitors (SSRIs). This includes fluoxetine or&#xD;
             fluvoxamine.&#xD;
&#xD;
          -  Patients on dextromethorphan, St. John's wort, cyclobenzaprine or other MAO inhibitors&#xD;
             (selective or non-selective)&#xD;
&#xD;
          -  Patients taking Antidepressants&#xD;
&#xD;
          -  Confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT greater&#xD;
             than 3 times the upper limit of the normal range)&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine more than 2.26 mg/dL)&#xD;
&#xD;
          -  Evidence of major psychiatric disorder or clinically evident dementia precluding&#xD;
             evaluation of symptoms&#xD;
&#xD;
          -  Known hypersensitivity to any component of the study drug&#xD;
&#xD;
          -  Liable to be not cooperative or comply with the trial requirements (as assessed by the&#xD;
             investigator), or unable to be reached in the case of emergency&#xD;
&#xD;
          -  Female with childbearing potential, if no adequate contraceptive measures are used&#xD;
&#xD;
          -  Pregnancy or breast-feeding females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C. Ludolph, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Technische Universität München</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>D-37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhrein-Westfalen</state>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>D-07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004 Sep;251(9):1080-4.</citation>
    <PMID>15372249</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>MD, Prof.</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>survival time</keyword>
  <keyword>ALS functioning Rating Scale</keyword>
  <keyword>quality of life</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

